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CLINICAL TRIALS AND OBSERVATIONS
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To evaluate in a prospective multicenter trial
the feasibility and clinical efficacy of the
combination of alemtuzumab (Campath-1H)
with the cyclophosphamide/doxorubicin/
vincristine/prednisone (CHOP) regimen
(CHOP-C) as the primary treatment for pa-
tients with peripheral T-cell lymphoma
(PTCL), between January 2003 and Decem-
ber 2005, 24 consecutive patients with PTCL
entered the study and received 8 CHOP
courses. Alemtuzumab was added at 30 mg
subcutaneously at day 1 initially to the
first 4 courses (4 patients), and then to all 8
courses (20 patients). Complete remission
(CR) was achieved in 17 (71%) patients, 1
had partial remission, and 6 had stable/
progressive disease. At a median follow-up
of 16 months (range, 5-42 months), 14 pa-
tients were alive, 9 had died from progres-
sive disease, and 1 had died from pneumo-
nia at day 198 while in CR. So far, 13 are
disease-free, with an overall median dura-
tion of response of 11 months. The most
frequent side effects were grade 4 neutrope-
nia and cytomegalovirus (CMV) reactiva-
tion. Major infections were Jacob-Creutzfeldt
(J-C) virus reactivation, pulmonary invasive
aspergillosis, Staphylococcus sepsis, and
pneumonia. This study shows that CHOP-C:
(1) is a feasible chemoimmunotherapy regi-
men; (2) is effective in PTCL with a high rate
of CR achievement; and (3) is associated
with mostly manageable infectious compli-
cations. This clinical trial was registered
with the Osservatorio Nazionale sulla Speri-
mentazione cinica as ID no. 141202. (Blood.
2007;110:2316-2323)
© 2007 by The American Society of Hematology
Introduction
In western countries, peripheral T-cell lymphomas (PTCLs)
account for 15% to 20% of aggressive lymphomas1 and for 7%
to 10% of all the non-Hodgkin lymphomas (NHLs).2,3 They
usually occur in middle to advanced age with a peak incidence
between the fifth and sixth decades, present as a widespread
disease in more than two-thirds of the patients, and show an
aggressive behavior, with more than half of the patients dying of
their disease within 1 year.2-4 Most authors agree about the
comparatively grim prognostic outcome of the T-cell phenotype
compared with a B-cell phenotype.3,5-10 The former remains a
negative prognostic factor in a multivariate analysis, and
appears to be independent from the International Prognostic
Index (IPI).11
The natural history of PTCL seems unaffected by second-
and third-generation chemotherapy regimens, and the 5-year
overall survival still remains between 25% and 47%.2-3,7-13
However, high-dose chemotherapy followed by autologous
hematopoietic stem cell transplantation (ASCT) has been suc-
cessfully performed in selected studies, mostly for resistant,
recurring disease.14-19 Corradini et al, in a cohort of 62 patients
with PTCL treated with a high-dose sequential program fol-
lowed by ASCT as front-line therapy, definitely demonstrated no
benefit of autologous bone marrow transplantation over standard
chemotherapy.20
CD52 antigen is present on normal and pathologic B and T cells,
with the highest values in T-prolymphocytic leukemia (T-PLL), as
shown by Ginaldi et al using quantitative flow cytometry.21 In PTCL,
however, CD52 expression varies from patient to patient, with an overall
expression rate lower than 50%.22 Nevertheless, CD52 can be a suitable
target for immunotherapy-based programs, given the availability of the
anti-CD52 humanized monoclonal antibody alemtuzumab (Campath-
1H; Schering AG, Berlin, Germany). Thus, a prospective multicenter
clinical trial was designed aimed to explore both the efficacy and the
safety of a chemo-immunotherapy approach based on the combination
of alemtuzumab with a standard-dose cyclophosphamide/doxorubicin/
vincristine/prednisone (CHOP) regimen as the first-line treatment for
patients with PTCL.
Submitted February 15, 2007; accepted June 14, 2007. Prepublished online as
Blood First Edition paper, June 20, 2007; DOI 10.1182/blood-2007-02-074641.
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Patients and methods
Patients
To be enrolled in the trial, patients had to meet the following criteria: (1) a
histologic diagnosis of PTCL unspecified (PTCL-U), angioimmunoblastic-
like T-cell lymphoma (AILD-T), or anaplastic large-cell T-cell lymphoma,
Alk-negative (ALCLAlk); (2) confirmation of the histopathologic diagno-
sis by the central review panel of expert pathologists of the University of
Bologna or, alternatively, by a second expert pathologist of another referral
center of pathology; (3) age greater than 16 years and less than 70 years;
(4) absence of major heart, liver, kidney, or gastrointestinal (GI) dysfunc-
tion except those related to lymphoma; (5) written informed consent;
(6) absence of uncontrolled infection; and (7) absence of other neoplasm or
previous chemo-radiotherapy.
From June 2003 to December 2005, patients with a diagnosis of PTCL
were consecutively enrolled in the trial by 14 Italian hematology institu-
tions on behalf of GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Overall, 25 patients were enrolled and assessed for feasibility and toxicity;
however, only 24 patients were evaluated for response, because 1 patient
had a revised diagnosis of lymphoblastic lymphoma after pathologic review
(see “Pathology review and CD52 expression”).
Pathologic review
The pathologic material was available from 22 of the 25 enrolled patients
and consisted of unstained sections (n  4) or paraffin blocks (n  18). The
material was used for both diagnostic review and immunohistochemical
localization of the CD52 molecule. In particular, the former was based on
the evaluation of hematoxylin-eosin–stained preparations and a series of
markers, including CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20,
CD21, CD30, CD56, CD79a, PAX5/BSAP, and Mib-1. It should be noted
that the markers could not be homogeneously assessed in all instances
because for 4 of the patients, only 10 unstained sections were available. The
corresponding antibodies were used following appropriate antigen retrieval
and detected using the alkaline phosphatase antialkaline phosphatase
(APAAP) complexes technique.23-24 Anti-CD52 (rat anti-human, monoclo-
nal; Serotec, Oxford, United Kingdom) was applied at a 1:200 dilution and
visualized with the EnVision technique, as previously described.23 Prior to
antibody exposure, the sections underwent antigen retrieval in citrate buffer
(pH  6.0) in a microwave at 900 W (3 cycles lasting 5 minutes each). Two
experienced pathologists (S.P. and C.C.) scored the CD52 results by
estimating the number of positive cells. Patients were considered positive if
30% or more of the tumor cells were stained.24
Study design
Main protocol features. The study protocol was a phase 2, open-label trial
performed among 14 Italian hematology institutions. The study was
approved by the ethics committee of the coordinating center (Hematology
Department of Cuneo Hospital) and subsequently approved by the local
ethics committee of the individual centers and by the national clinical trials
agency. Written informed consent was obtained according to the Declara-
tion of Helsinki.
The primary end points of the study were feasibility and toxicity of the
treatment program; the secondary end point was the efficacy of the
program, assessed in terms of achievement of complete remission (CR),
1-year overall survival (OS), and 1-year failure-free survival (FFS).
To prevent excessive immunosuppression induced by alemtuzumab
when administered once a month for 8 months, the treatment program was
split into 2 therapeutic schedules, differing only in the number of
alemtuzumab infusions, and stopping rules were introduced. Phase 1 con-
sisted of 4 courses of CHOP-C (CHOP supplemented with alemtuzumab),
and 4 courses of standard CHOP. Phase 2 followed, consisting of 8 courses
of CHOP-C. The first 4 patients enrolled were allocated to phase 1; in the
absence of a serious adverse event (SAE; see “Study design, stopping
rules”) in Phase 1, the study shifted to Phase 2 with the second group of
patients. Had a single SAE been reported during phase 1, an additional
patient would have been enrolled in this phase. If another patient within this
group had developed a SAE, the trial would have been closed. The same
protocol of stopping rules was planned for phase 2. A SAE was defined as
any adverse event directly related to the therapy, occurring both during
therapy or follow-up, including (1) death, (2) life-threatening complica-
tions, (3) disabling conditions, or (4) a prolonged hospitalization (more than
3 months).
Treatment schedule. The treatment schedule is summarized in Figure
1. In the first cohort of patients (patients 1-4: phase 1) alemtuzumab was
given only at courses 1 through 4, and standard CHOP was administered for
courses 5 through 8. In the second cohort (patients 5-25: phase 2),
alemtuzumab was administered at all CHOP courses. Patients were given
standard-dose CHOP chemotherapy for 8 courses as previously reported.25
Cycles were repeated every 28 days. At the first course, alemtuzumab was
given subcutaneously with an escalated dose of 3 mg, 10 mg, and 30 mg on
days2,1, and 0, respectively, and the full 30-mg dose was given the day
before for subsequent courses. Chlorphenamine (10 mg) was given
intravenously 1 hour prior to alemtuzumab administration, along with
500 mg paracetamole orally and 100 mg alizapride intravenously, which
were administered 30 minutes prior to alemtuzumab administration.
Sample size. A single-stage phase 2 study design was used to test the
null hypothesis that the true response rate was 40% to 45% against the
alternative that it was 70%. A sample size of 25 evaluable patients was
planned, using A’Hern’s tables for exact single-stage phase 2 designs.26 If
15 or more responses were observed, the null hypothesis would be rejected.
With this scenario, the probability of 1-sided type I error was .05, and the
study power was .90.
Anti-infective prophylaxis. Prophylaxis against herpes simplex virus
(HSV) and varicella-zoster herpes virus (HVZ), regardless of a history of
previous recurrent disease, was given to all patients with 400 mg acyclovir
twice in a day. Prophylactic therapy against Pneumocystis carinii with
800/160 mg sulphametoxazole-trimethoprim tablets twice a day on alter-
nate days was given, or pentamidine aerosol every 45 days in case of
allergic reaction to cotrimoxazole. Ciprofloxacin (500 mg) twice a day was
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Figure 1. Two-phase schedule of CHOP-C administration.
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administered when neutrophil count decreased below 500/L. The galacto-
mannan assay for monitoring invasive aspergillosis was performed twice
a week in most patients, and 400 mg/day itraconazole in oral solution, was
administered during meals. Both galactomannan monitoring and antifungal
prophylaxis were performed throughout the treatment and prolonged up to
6 months after the end of the chemotherapy. In case of 2 consecutive
positive assays, antifungal therapy was started.
Stopping rules. As mentioned, the study was split into 2 phases based
on the total dose of alemtuzumab administered and allowed for only
1 patient in phase 1 and 1 patient in phase 2 to present with a SAE. If any
other patient beyond this threshold had developed a SAE, the study would
have been closed. This protocol follows standard stopping rules as required
for clinical trials conducted in good clinical practice.
Disease evaluation
Patients underwent a baseline staging with physical examination, involving
a measurement of all the superficial pathologic nodes, complete blood count
(CBC), routine laboratory tests with liver and kidney function assessment,
serologic testing for anamnestic viral and fungal infection, total and
differential count of CD3, CD4, and CD8 lymphocyte counts, chest and
abdominal CT and/or positron emission tomography (PET) scan, and
bilateral bone marrow trephine biopsy. The same hematologic, biochemical,
and radiologic tests were repeated at the end of the therapy and every
6 months thereafter during follow-up. Bone marrow trephine biopsy was
repeated in the presence of bone marrow invasion at diagnosis. The
response assessment was made according to the Eastern Cooperative
Oncology Group (ECOG) criteria of response to therapy for NHL.27-28
Statistical analysis
All data were analyzed using the SAS program (SAS Institute, Cary, NC).29
OS and FFS curves were calculated according to the Kaplan-Meier
method.30 OS was calculated from the date of diagnosis until death from
any cause or date of last contact for living patients. For patients in CR, FFS
was calculated from the date of diagnosis to the first evidence of failure.
Failure was defined as (1) any treatment response different from CR or
partial remission (PR), (2) disease relapse, (3) death from lymphoma, or
(4) death from treatment effects.
Results
Pathology review and CD52 expression
The diagnosis of PTCL was confirmed by the central review panel
in 19 of 22 patients, and defined according to the World Health
Organization (WHO) Classification (8 with PTCL-U, 7 with
AILD-T, 3 with ALCL Alk, and 1 with enteropathy-associated
T-cell lymphoma [EATCL]).3 The bioptic sample was insufficient
in 2 patients, while the original diagnosis was not confirmed for
1 patient, who was diagnosed with T-lymphoblastic lymphoma
(TdT) at the pathologic review. In 3 patients (2 with PTCL-U and
1 with ALCL ALK), the diagnosis was confirmed by the local
referral pathologists. CD52 was analyzed in 19 of 24 patients. In
5 patients, a CD52 assay could not be done either for absence
(3 patients) or insufficient material (2 patients). CD52 was evalu-
able in 15 of 19 patients, 11 that were CD52 and 4 that were
CD52. In the remaining 4 patients (2 with unstained sections and
2 with paraffin blocks available), antigen preservation was on the
whole poor as shown by the immunohystochemical results for most
antibodies used.
Clinical characteristics of the patients
The clinical characteristics of the 24 patients evaluable for both
toxicity and response to CHOP-C are reported in Table 1. The
mean age was 52.0 years (range, 28-69 years), and all but
3 showed advanced disease (stages III-IV). Bulky disease was
recorded in 2 patients, bone marrow involvement in 10 patients,
high lactose dehydrogenase (LDH) values in 12 patients, and an
IPI of 0 in 1 patient, 1 in 7 patients, 2 in 7 patients, 3 in
7 patients, and 4 in 2 patients.
Treatment feasibility and dose intensity
Overall, 25 patients entered the study protocol and were
valuable for treatment feasibility and toxicity. Patients 1 through
4 were treated with CHOP-C for 4 cycles, followed by 4 courses
of standard CHOP; patients 5 through 21 received the planned
8 CHOP-C courses, while only 6 CHOP-C courses were
delivered to patients 22 through 25, as a result of individual
physician decision.
The relative dose intensity (RDI) was calculated according
to Hryniuk and Bush.31 The mean dose intensity was
210 mg/m2/week (RDI  96%) for cyclophosphamide, 14 mg/
m2/week (RDI  90%) for doxorubicin, 0.29 mg/m2/week
(RDI  94%) for vincristine, 85 mg/m2/week (RDI  59%) for
prednisone, and 8.0 mg/m2/week for alemtuzumab (RDI  88%).
In 1 patient, aged 69 years, vincristine was administered at
half-dose for all CHOP-C courses (1 mg every cycle). The RDI
was slightly lower for alemtuzumab and prednisone because in
2 patients who developed invasive aspergillosis due to severe
immunodepression, both drugs were reduced.
Treatment response
Response is summarized in Table 2. Among 24 evaluable
patients, 17 (71%) reached CR and 1 had PR, with an overall
response rate (CP  PR) of 75%; the remaining patients had
either stable or progressive disease. All the patients affected by
AILD-T (6 of 6), ALCL (3 of 3), and EATCL (1 of 1) entered
CR, while only 50% of PTCL-U patients (7 of 14) showed a CR.
CD52 expression could be evaluated in 15 patients: 4 were
found negative and 11 positive. Two of the 4 patients with a
CD52 phenotype progressed during therapy and 2 patients
entered CR, while 8 (73%) patients with the CD52 phenotype
reached CR.
As shown in Table 2, after a mean follow-up of 495 days
(range, 217-1186 days), 14 of 24 patients were still alive, and
Table 1. Main patient characteristics
Parameter Value
Number of patients* 24
Age, median y (range) 52 (28-69)
Histologic subtype, no. patients (%)
PTCL-U 14 (58.3)
AILD-T 6 (25.0)
ALC-Alk 3 (12.5)
EATCL 1 (4.2)
Ann Arbor stage III IV, no. patients (%)
III-IV 21 (87.5)
B symptoms, no. patients (%) 11 (45.8)
Bone marrow involvement, no. patients (%) 10 (41.7)
Elevated LDH serum level, no. patients (%) 12 (50.0)
IPI score, no. patients (%)
0-1 8 (33.3)
2-3 14 (58.3)
4-5 2 (8.3)
*A total of 25 patients entered the study program and were evaluable for
treatment feasibility and toxicity; however, 1 patient had a revised diagnosis of
lymphoblastic lymphoma and was excluded from the response analysis.
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10 had died. Of the 24 patients, 17 achieved CR, 1 achieved PR,
and 1 achieved minimal response (MR). A total of 5 patients
showed progression early during therapy: 1 after 2 courses,
1 after 3 courses, and 3 after 4 courses. At the last follow-up
December 31, 2006, 14 patients were alive. So far, 9 patients
have died as a result of resistant lymphoma, including the
7 patients not in CR at the end of treatment and 2 patients in
relapse; 1 more patient died from pneumonia while in CR,
6 months after treatment completion; this complication could be
a consequence of the immunosuppressive treatment and there-
fore considered as a treatment failure. A total of 13 patients are
presently in continuous CR, while 4 patients (3 in CR and 1 in
PR) experienced disease relapse at 3, 4, 5, and 8 months after
treatment completion.
As shown in Figure 2A, the OS curve is projected to 70% and
53% at 1 and 2 years, respectively. As shown in Figure 2B, the FFS
curve is projected to 54% and 48% at 1 and 2 years, respectively.
Adverse events
Toxicity was evaluated for all 25 patients who were treated with
CHOP-C for a total of 176 courses.
Infusion-related. Infusion-related adverse events were re-
corded after alemtuzumab administration in 7 patients: a mild
febrile spike (up to 38°C) was transiently observed in 4 patients at
different CHOP-C administrations, and 3 more patients occasion-
ally displayed a local erythema around the injection site during the
first 3 courses. No grade 4 reactions were observed.
Hematologic toxicity. Neutropenia was by far the most fre-
quent manifestation of hematologic toxicity, with severe neutrope-
nia recorded in 59 (34%) of 176 cycles. Thrombocytopenia was
less frequent, and severe thrombocytopenia was observed in only
4 (2%) of 176 cycles. Anemia was even less frequent, and a
reduction of more than 20 g/L (2 g/dL) hemaglobin compared with
the baseline values was recorded in 6 (25%) of 24 patients at the
end of treatment. The most severe hematologic toxicities were
usually observed following the first CHOP-C course. Combined
alemtuzumab and CHOP administration produced a profound
decline in circulating T-lymphocytes: mean CD3, CD4, and CD8
values before treatment were 1042, 529, and 394 cells/L,
respectively, while these values dropped to 239, 156, and
305 cells/L, respectively, after treatment. The values steadily
increased thereafter and reached normal levels within 6 months in
all but 2 patients.
Nonhematologic toxicity. Infectious complications were by far
the most frequent nonhematologic toxicities (Table 3). Cytomega-
lovirus reactivation, without evidence of pneumonia, was diag-
nosed by immunofluorescent detection of p65-bearing leukocytes
and/or viral DNA detection by polymerase chain reaction (PCR)
analysis in at least 2 consecutive samples. With these diagnostic
tools, CMV reactivation was detected in 15 (9%) of 176 courses.
All patients diagnosed with CMV reactivation received preemptive
foscarnet or gancyclovir, usually with a rapid return to normal
serologic results and disappearance of any symptoms possibly
related to CMV reactivation. In 1 patient, left facial nerve palsy and
hyposthenia in a left lower limb appeared 1 month after the
completion of the chemotherapy: a cranial nuclear magnetic
resonance (NMR) showed a picture evocative of J-C virus encepha-
litis, and the diagnosis was confirmed in cerebrospinal fluid (CSF)
fluid by PCR. The patient is now in continuous CR but with a
clinical picture of irreversible dementia: this complication is
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Figure 2. Kaplan-Meier estimates of distribution function of all 24 patients. (A) OS. (B) FFS.
Table 2. Response to treatment of 24 evaluable patients with PTCL
Response parameter
Histopathology,
proportion Total no. (%)
CR
PTCL-U 7/14 17 (70.8)
AILD-T 6/6 —
ALCL 3/3 —
EATCL 1/1 —
PR
PTCL-U 1/14 1 (4.2)
Minor response
PTCL-U 1/14 1 (4.2)
Disease progression
PTCL-U 5/14 5 (20.8)
Patients alive
PTCL-U 5/14 14 (58.3)
AILD-T 6/6 —
ALCL 3/3 —
Median follow-up, mo (range) — 16 (5-42)
Patients alive in CCR
PTCL-U 5/14 13 (54.2)
AILD-T 5/6 —
ALCL 3/3 —
Median follow-up, mo (range) — 11 (5-42)
— indicates not applicable.
CHOP, Campath-1H, PTCL 2319BLOOD, 1 OCTOBER 2007  VOLUME 110, NUMBER 7  personal use only.
For at Biblioteche biomediche Università di Torino on May 18, 2012. bloodjournal.hematologylibrary.orgFrom 
related to the severe immunosuppression induced by the treatment
and therefore should be considered a treatment failure. Two
patients developed invasive aspergillosis. The first patient devel-
oped a lung infiltrate after the third CHOP-C course and was
treated with voriconazole for 4 months with complete clearance of
the lesion. This patient received a fourth CHOP course without
alemtuzumab with approximately a 1-month delay, then received
the remaining 4 courses regularly, all supplemented with alemtu-
zumab. The second patient developed pulmonary invasive aspergil-
losis after the fourth CHOP-C course, and underwent systemic
antifungal therapy for a month, with a favorable outcome; this
patient also resumed the therapy with a 1-month delay. One patient
developed Pneumocistis carinii pneumonia, treated successfully
with cotrimoxazole. Bacterial infectious complications included
1 patient with Staphylococcus aureus sepsis related to the surgical
biopsy and 1 with Streptococcal sepsis; both responded to wide-
spectrum antibiotics. There also was 1 patient with bacterial
pneumonia sensitive to wide-spectrum antibiotics, occurring after
the fifth cycle. Enlarged abdominal nodes were observed in
1 patient after the 8 CHOP-C courses: ultrasound fine-needle
biopsy showed granulomatous adenopathy with Ziehl-Nielsen
elements, probably related to atypical mycobacteriosis; however,
re-evaluation 3 months later showed the almost complete disappear-
ance of the abdominal nodes without any specific treatment.
Finally, 1 patient developed fever of unknown origin (FUO) after
the eighth CHOP-C course that was resistant to empiric antibiotic
therapy; the fever subsided upon resolution of neutropenia without
any microbiological evidence of a specific etiologic agent.
Other mild side effects. A total of 3 patients showed signs of
neurotoxicity: 2 presented a grade 2 obstinate constipation
probably related to itraconazole, and 1 presented a grade
2 peripheral neuropathy.
Discussion
The present study reports the results of a prospective multicenter
trial to evaluate the feasibility, safety, and efficacy of the combina-
tion of alemtuzumab and CHOP (CHOP-C) as first-line treatment
for patients with PTCL. Alemtuzumab was used at a low dosage of
30 mg per CHOP course, which helped make the program feasible.
Indeed, CHOP-C was deliverable to all patients, with minor dose
reductions in a few instances. Nevertheless, infectious complica-
tions were not only frequent but also severe and life-threatening in
a few patients. On the other hand, alemtuzumab given at 30 mg
along with CHOP-C produced a high rate of stable CR. This
result is quite encouraging and suggests that chemo-immuno-
therapy may represent a major advance in the management of
PTCL, provided that careful monitoring and prompt treatment of
infectious complications are implemented in those new sched-
ules that include alemtuzumab.
The term PTCL designates an heterogeneous group of T-cell
malignancies characterized by an aggressive behavior and a dismal
prognosis, with less than 30% of patients being cured by
anthracycline-containing therapies, such as CHOP or CHOP-
like regimens,2-4,8-9,12 Because of these disappointing results,
other strategies have been explored, including high-dose chemo-
therapy and autografting. So far, most of the published studies
with ASCT both as salvage or first-line therapy have failed to show
any significant advantage over standard treatment with standard
chemotherapy (CHOP or CHOP-like regimens).13-18,20,32 Two
recent publications have prospectively explored the role of
ASCT as a first-line treatment after high-dose chemotherapy in
an intent-to-treat and long-term analysis, and both failed to
show any advantage over standard treatment.20,33 Chemo-
immunotherapy combining antilymphoma cell monoclonal anti-
body and chemotherapy is presently the most innovative and
effective approach in the management of lymphoma, specifi-
cally B-cell subtypes.34-36 The CD52 antigen seems a suitable
target for chemo-immunotherapy programs for PTCL, given the
availability of the anti-CD52 alemtuzumab. The glycosylphos-
phatidylinositol-anchored membrane glycoprotein CD52 is
detectable by cytofluorimetric assay on normal and pathologic
B- and T-cell populations, with the highest values observed in
some T-cell neoplasms such as T-PLL, although the expression
of this molecule has been found detectable in less than 50%
of PTCL samples evaluated using a standard immunohisto-
chemical procedure.21-22
The inclusion of alemtuzumab in therapeutic programs for
T-cell disorders has been considered with increasing interest in
the last few years. Preliminary observations have shown some
promising results in different T-cell malignancies, including
T-PLL, cutaneous T-cell lymphomas, and T-cell large granular
lymphocytic leukemia.37-40 So far, a single study has been
performed with alemtuzumab in PTCL in a series of 14 patients
with PTCL failing 1 or 2 lines of chemotherapy. Alemtuzumab
was given alone at 30 mg subcutaneously 3 times a week for a
maximum of 12 weeks and produced an overall response rate of
36%, with 3 patients achieving CR and 2 patients achieving PR.
Despite these encouraging results, the study was closed because
of unacceptably high toxicity, with 5 treatment-related deaths.41
Quite recently, a very preliminary report has been published on
20 patients treated with CHOP-C with the same schedule of the
present study, with courses repeated every 21 days. The CR rate
was 65%, and the estimated event-free survival at 1 year was
43%.42 These results, albeit similar to ours, are the report of
an interim analysis of an ongoing trial and are too preliminary
for a comment.
These considerations taken together prompted us to design a
prospective trial to evaluate alemtuzumab in combination with
chemotherapy in PTCL. In planning the trial, we carefully
considered the following main issues: (1) the very aggressive
behavior of PTCL; (2) the potential risks of infectious complica-
tions with alemtuzumab; (3) the need to combine alemtuzumab
with a chemotherapy program well defined for both toxicity and
clinical efficacy; and (4) the unequivocal histopathologic diagno-
sis of PTCL of patients entering the study protocol. Thus, a
Table 3. Major (WHO 4) infections
Patient no. CIC Age, years Histopathology Infection
2 UD1 57 PTCL-U Invasive aspergillosis, J-C viral encephalitis
4 GE1 64 ALK- Staphylococcus sepsis, Streptococcus sepsis
7 SP1 65 PTCL-U Bacterial pneumonia, PC pneumonia
15 TO1 69 PTCL-U Bacterial pneumonia, invasive aspergillosis
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study protocol was designed for patients with PTCL at disease
onset; the program included the use of a standard CHOP
regimen supplemented with alemtuzumab. To prevent excessive
immunosuppression, the dose of alemtuzumab was 30 mg in
each course, which represents a much lower dosage compared
with that used in previous studies; the cycles were administered
every 4 weeks instead of 3 weeks. A histopathologic review of
the diagnostic sample was performed in all instances.
Combining alemtuzumab with standard CHOP chemo-
therapy proved to be quite effective in terms of treatment
response: 18 patients responded with an overall response rate of
75%: 17 patients entered CR, and 1 entered PR. Of the 17
patients in CR, the response was durable in 14 patients, with a
median CR duration of 11 months. This result compares
favorably with the less than 50% CR rate reported with CHOP or
CHOP-like regimens.2,3,8,13 At this writing, only 3 of the 17
patients in CR and 1 patient in PR have relapsed. The results are
even more relevant if one considers that all but 3 patients
showed at presentation an advanced stage, with a high LDH
value in half of them (50%), bone marrow involvement in 41%,
and an age older than 60 years in one-third of patients. All these
parameters have been shown to have adverse prognostic signifi-
cance in the prognostic index for peripheral T-cell lymphoma
unspecified (the so-called PIT model).4 Indeed, the median CR
duration of 11 months looks quite promising if one considers
that almost half of the patients with PTCL die because of their
disease within 1 year following conventional treatments.4
Although the numbers in this study were very small, the patients
treated with 8 CHOP-C courses seemed to respond better than
the ones treated with 4 CHOP-C courses: 33% versus 76%,
respectively. This outcome could suggest that the second
schedule is the efficacious one, and could prompt us to plan a
future treatment schedule with CHOP-C 21 or even CHOP-C 14
instead of CHOP-C 28.
The histopathologic diagnosis was carefully reviewed in all
patients, with additional immunohistochemical studies in most
diagnostic samples. In addition, expression of CD52 was assessed
whenever possible. In our series, 11 of 15 evaluable patients had
neoplastic cells positive for CD52, with a higher percentage than
those found by Rodig et al22 and Piccaluga et al.43 It has been
reported that CD52 expression might correlate with treatment
outcome in T-PLL.21 However, we could not show any relationship
between CD52 expression and treatment outcome in our series, but
this might reflect the limited number of patients enrolled. The same
holds true for the CD52 positivity prevalence among patients with
PTCL recorded in the present study: for instance, Piccaluga et
al—who obtained much lower figures—evaluated 93 patients.43
Thus, prospective studies on larger collectives are warranted to
understand predictive value of CD52 determination. Our results
might indicate that the intensity rather than the percentage of CD52
expression by neoplastic cells is relevant and may predict tumor
response to alemtuzumab. This hypothesis is supported by recent in
vitro observations in experimental models.44 Alternatively, one can
speculate that alemtuzumab might eliminate surrounding normal
CD52 cells, leading to damage to the microenvironment and, as a
consequence, to a weakened survival of neoplastic cells. Whatever
the mechanisms, the combination of alemtuzumab and CHOP
represents an innovative and really effective treatment for a disease
poorly responsive to currently available therapies.
Despite a thorough program of anti-infective prophylaxis and
watchful clinical monitoring, the main problem we faced in our
study was the high incidence and severity of infectious complica-
tions. Indeed, life-threatening infections occurred in one-quarter of
the patients (2 instances of invasive aspergillosis, 1 instance of J-C
viral encephalitis, 2 instances of sepsis, 2 instances of pneumonia,
and 1 instance of suspected tuberculosis). The total and differential
T-cell counts were not checked cycle by cycle in all the patients: in
3 patients, the CD3 values dropped below 500 cells/L after the
third course of chemotherapy: for these reasons the severe
T depletion could reasonably be the main cause for these serious
infections. These numbers confirm that alemtuzumab therapy is
associated with marked immunosuppression and consequently with
an increased risk of infections by various agents, as already
observed in previous experiences with alemtuzumab in patients
with T-cell disorders.38-39,41 Moreover, in a few patients, transient
severe neutropenia or even pancytopenia were observed; however,
incidence, degree, and duration were similar to those reported in
previous studies with alemtuzumab in PTCL.38,39,41 In fact, the
main toxicity associated with alemtuzumab is probably the suppres-
sion of T-cell function and the absolute drop in the number of CD4
cells. These factors are responsible for the opportunistic infections
that remain the most serious problem during and after alemtu-
zumab administration. Attempts to minimize the risk of infectious
complication, using new strategies such as preemptive therapies
based on a very early diagnosis of viral or fungal infection and/or
the infusion of cytotoxic T lymphocytes (CTLs) raised against
specific viral or fungal targets should be possibly considered and
included in alemtuzumab-containing programs.45-46 A number of
new drugs less immunosuppressive are at present under evaluation
in PTCL: among these are gencytabine alone47 or in combination,48
the histone deacetylase inhibitors depsipeptide49 and SAHA,50 the
purine analog nelarabine,51 and new antifolate drugs such as
pralatrexate. All these drugs showed a mild to moderate activity in
PTCL, with the noteworthy exception of pralatrexate: the latter, in
a phase 2 pilot study, was able to induce CR in 4 out of 5 patients
with heavily pretreated PTCL. Of the 4 responding patients,
3 remained in CR for 4 to 9 months, with no other side effects than
a mild stomatitis.52
In conclusion, the results of our prospective trial demonstrate
that CHOP-C is a practicable and effective regimen for patients
with PTCL at diagnosis, inducing a high rate of CR; its efficacy,
however, could be potentially hampered by the nonnegligible
percentage of infectious complications reported in this study: at
this writing, a number of phase 3 randomized trials comparing
CHOP-C followed by ASCT to traditional CHOP or CHOP-like
regimens followed by the same intensive regimen are under way.
Only these randomized trials could clarify the confines of the
risk-benefit ratio of this combination regimen. Recently encourag-
ing results in terms of OS and PFS have been reported using
reduced-intensity conditioning (RIC) allogeneic transplantation in
patients with relapsed or primary refractory PTCLs.53 Based on
these findings, it has been suggested that patients with an HLA-
identical donor and poor prognostic features at diagnosis might be
included in investigative trials of RIC, followed by allografting.
However, an adequate tumor reduction if not a complete remission
is a prerequisite for a successful allogeneic procedure. Thus,
CHOP-C can be considered a suitable up-front treatment for
PTCLs that ensures a high response rate; responsive patients with
an adverse prognostic presentation and an HLA-identical donor
may subsequently be considered for RIC allograft. This combined
approach is now under evaluation in an ongoing multicenter study
at our institutions in Italy.
CHOP, Campath-1H, PTCL 2321BLOOD, 1 OCTOBER 2007  VOLUME 110, NUMBER 7  personal use only.
For at Biblioteche biomediche Università di Torino on May 18, 2012. bloodjournal.hematologylibrary.orgFrom 
Acknowledgments
We thank Cristina Campidelli from the pathology chair of the
University of Bologna for having cooperated in the pathology
review of the diagnostic material.
This work was supported in part by research funding from Schering
AG to A.G.
Authorship
Contribution: A.G. designed research and wrote the paper; C.T.
designed research and reviewed the paper; F.Z. reviewed the paper;
P.T. analyzed the data; S.P. reviewed the histopathology and
reviewed the paper; and all the authors but S.P. and P.T. collected
clinical data.
A complete list of the participating institutions in Gruppo
Italiano Terapie Innovative nei Linfomi can be found in the
Appendix.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Dr. Andrea Gallamini, Hematology Depart-
ment, Azienda Ospedaliera S. Croce e Carle Via M Coppino,
26-12100 Cuneo, Italy. email: gallamini.a@ospedale.cuneo.it.
Appendix
Gruppo Italiano Terapie Innovative nei Linfomi (GITIL) Membership: P.
Leoni and M. Montanari: University Division of Hematology at Torrette
Hospital, Ancona, Italy; S. Rambaldi and T. Barbui: Division of Hematol-
ogy at Ospedali Riuniti, Bergamo, Italy; S. Cortelazzo: Division of
Hematology at Ospedale Santa Maurizio, Bolzano, Italy; G. La Nasa:
University Division of Hematology at Ospedale Binaghi, Cagliari, Italy; F.
Di Raimondo and G. Palumbo: University Division of Hematology at
Ospedale Ferrarotto, Catania, Italy; A. Gallamini: Division of Hematology
at Ospedale Santa Croce, Cuneo, Italy; A.M. Gianni: University Division of
Oncology at Istituto Nazionale per la cura dei Tumori (INT), Milan, Italy; P.
Corradini: University Division of Hematology at Istituto Nazionale per la
cura dei Tumori (INT), Milan, Italy; F. Ciceri: University Division of
Hematology at Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Ospedale San Raffaele, Milan, Italy; G. Semenzato: University Division of
Hematology, Milan, Italy; S. Mirto and C. Patti: Division of Hematology at
Ospedale Vincenzo Cervello, Palermo, Italy; B. Falini and M. Martelli:
University Division of Hematology at Policlinico Monteluce, Perugia,
Italy; A. Olivieri: Division of Hematology at Ospedale San Carlo, Potenza,
Italy; I. Majolino and V. Zoli: Division of Hematology at Ospedale San
Camillo/Forlanini, Rome, Italy; S. Amadori and M. Cantonetti: University
Division of Hematology at Torvergata University, Rome, Italy; G. Saglio
and G. Parvis: University Division of Internal Medicine at San Luigi
Hospital, Orbassano [Torino], Italy; C Tarella and M. Ladetto: University
Division of Hematology at San Giovanni Hospital, Torino, Italy; G. Pizzolo
and F. Benedetti: University Division of Hematology, University and
Hospital of Verona, Italy.
References
1. Coiffier B, Berger F, Byron PA, et al. T-cell lym-
phomas: immunological, histological, clinical and
therapeutic analysis of 63 cases. J Clin Oncol.
1988;6:1584-89.
2. Ascani S, Zinzani PL, Gherlinzoni F, et al. Periph-
eral T-cell lymphomas: clinico-pathologic study of
168 cases diagnosed according to the R.E.A.L.
classification. Ann Oncol. 1997;8:583-92.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tu-
mours of haematopoietic and lymphoid tissue. In:
Pathology & Genetics. Lyon, France: IARC Press;
2001:189-235.
4. Gallamini A, Stelitano C, Calvi R, et al. Peripheral
T-cell lymphoma unspecified (PTCL-U): a new
prognostic model from a retrospective multicen-
tric clinical study. Blood. 2004;103:2474-2479.
5. Cheng AL, Chen YC, Wang CH, et al. Direct com-
parison of peripheral T-cell lymphoma with diffuse
B-cell lymphoma of comparable histological
grades: should peripheral T-cell lymphoma be
considered separately? J Clin Oncol. 1989;7:725-
31.
6. Kwak LW, Wilson M, Weiss LM, et al. Similar out-
come of treatment of B-cell and T-cell diffuse
large cell lymphomas: the Stanford experience.
J Clin Oncol. 1991;9:1426-33.
7. Coiffier B, Brousse N, Peuchmaur M, et al. Pe-
ripheral T-cell lymphomas have a worse progno-
sis than B-cell lymphomas: a prospective study of
361 immunophenotyped patients treated with the
LNH84 regimen. Ann Oncol. 1990;1:45-50.
8. Melnyk A, Rodriguez A, Pugh WC, Cabanillas F.
Evaluation of the revised European-American
lymphoma classification confirms the clinical rel-
evance of immunophenotype in 560 cases of ag-
gressive non-Hodgkin’s lymphoma. Blood. 1997;
89:4514-20.
9. Gisselbrecht C, Gaulard P, Lepage E, et al. Prog-
nostic significance of T-cell phenotype in aggres-
sive non-Hodgkin’s lymphomas Blood. 1998;92:
76-82.
10. Lopez-Guillermo A, Cid J, Salar A, et al. Periph-
eral T-cell lymphomas: initial features, natural his-
tory and prognostic factors in a series of 174 pa-
tients diagnosed according to the R.E.A. L.
classification. Ann Oncol. 1998;9:849-55.
11. Ansell SM, Habermann TM, Kurtin PJ, et al. Pre-
dictive capacity of the International Prognostic
Factor Index in patients with peripheral T-cell lym-
phomas. J Clin Oncol. 1997;15:2296-301.
12. Zaja F, Russo D, Silvestri F, et al. Retrospective
analysis of 23 cases with peripheral T-cell lym-
phoma, unspecified: clinical characteristics and
outcome. Haematologica. 1997;82:171-77.
13. Rudiger T, Weisenburger DD, Anderson JR, et al.
Peripheral T-cell lymphoma (excluding large-cell
lymphoma): results from the Non-Hodgkin’s Lym-
phoma Classification Project. Ann Oncol. 2002;
13:140-149.
14. Haioun C, Lepage E, Gisselbrecht C, et al. Ben-
efit of autologous bone marrow transplantation
over sequential chemotherapy in poor-risk ag-
gressive non-Hodgkin’s lymphoma: updated re-
sults of the prospective study LNH87-2. J Clin
Oncol. 1997;15:1131-37.
15. Rodriguez J, Munsell M, Yazji S, et al. Impact of
high-dose chemotherapy on peripheral T-cell lym-
phomas. J Clin Oncol. 2001;19:3766-3770.
16. Rodriguez J, Caballero MD, Gutierrez A, et al.
High dose chemotherapy and autologous bone
marrow transplantation in patients with peripheral
T-cell lymphoma not achieving complete re-
sponse after induction chemotherapy: the GEL-
TAMO experience. Haematologica. 2003;88:
1372-1377.
17. Rodriguez J, Caballero MD, Gutierrez A, et al.
High-dose chemotherapy ant autologous stem
cell transplantation in peripheral T-cell lymphoma:
the GEL-TAMO experience. Ann Oncol. 2003;14:
1768-1775.
18. Jantunten E, Wilkund T, Juvonen E, et al. Autolo-
gous stem cell transplantation in adult patients
with peripheral T-cell lymphoma: a nation-wide
survey. Bone Marrow Transplant. 2004;33:405-
410.
19. Kewalramani T, Zelenetz AD, Teruya-Feldstein J,
et al. Autologous transplantation for relapsed or
primary refractory peripheral T-cell lymphoma.
Br J Haematol. 2006;134:202-207.
20. Corradini P, Tarella C, Zallio E, et al. Long-term
follow-up of patients with peripheral T-cell lym-
phomas treated up-front with high-dose chemo-
therapy followed by autologous stem cell trans-
plantation. Leukemia. 2006;20:1533-1538.
21. Ginaldi L, De Martinis M, Matutes E, et al. Levels
of expression of CD 52 in normal and leukemic B
and T cells: correlation with in vivo therapeutic
responses to Campath-1H. Leuk Res. 1998;22:
185-191.
22. Rodig SJ, Abramson JS, Pinkus GS, et al. Heter-
ogeneous CD52 expression among hematologic
neoplasms: implications for the use of alemtu-
zumab (CAMPATH-1H). Clin Cancer Res. 2006;
12:7174-7179.
23. Sabattini E, Bisgaard K, Ascani S, et al. The En-
Vision system: a new immunohistochemical
method for diagnostics and research: critical
comparison with the APAAP, ChemMate, CSA,
LABC, and SABC techniques. J Clin Pathol.
1998;51:506-511.
24. Went P, Agostinelli C, Gallamini A, et al. Marker
expression in peripheral T-cell lymphoma: a pro-
posed clinical-pathologic prognostic score. J Clin
Oncol. 2006;24:2472-2479.
25. Fisher IF, Gaynor EL, Martin D, et al. Comparison
of a standard regimen (CHOP) with three inten-
sive chemotherapy regimens for advanced Non-
Hodgkin’s Lymphoma. N Engl J Med. 1993;328:
1002-1006.
26. A’Hern RP. Sample size tables for exact single-
stage phase II designs. Stat Med. 2001;20:859-
866.
27. Oken MM, Creech RH, Tommey DC, et al. Toxic-
ity and response criteria of the Eastern Coopera-
tive Oncology Group. J Clin Oncol. 1982;5:649-
655.
28. Cheson BD, Horning SJ, Coiffier B, et al. Report
2322 GALLAMINI et al BLOOD, 1 OCTOBER 2007  VOLUME 110, NUMBER 7 personal use only.
For at Biblioteche biomediche Università di Torino on May 18, 2012. bloodjournal.hematologylibrary.orgFrom 
of an International workshop to standardize re-
sponse criteria for non-Hodgkin’s lymphoma.
J Clin Oncol. 1999;17:1244-1253.
29. SAS 9.1.3 user’s guide: help and documentation.
Cary, NC: SAS Institute; 2000-2004.
30. Kaplan EL, Meier P. Nonparametric estimation
from incomplete observation. JAMA. 1958;53:
457-481.
31. Hryniuk W, Bush H. The importance of dose in-
tensity in chemotherapy of metastatic breast can-
cer. J Clin Oncol. 1984;2:1281-1288.
32. Savage K. Aggressive peripheral T-cell lym-
phoma (specified and unspecified types). Hema-
tology. Am Soc Hematal Educ Program. 2005;
267-277.
33. Reimer P, Rudiger T, Wilhelm M. The role of high-
dose therapy in peripheral T-cell lymphoma. Clin
Lymphoma Myeloma. 2006;6:373-9.
34. Hiddemann W, Buske C, Dreyling M, et al. Treat-
ment strategies in follicular lymphomas: current
status and future perspectives. J Clin Oncol.
2005;23:6394-9.
35. Tarella C, Gianni AM. BMT for lymphoma CR1.
Curr Opin Oncol. 2005;17:99-105.
36. Gisselbrecht C, Mounier N. Managing large cell
lymphoma: symposium article. Ann Oncol. 2006;
17:iv4-iv11.
37. Dearden C. The role of Alemtuzumab in the man-
agement of T-cell malignancies. Sem. Oncol.
2006;33:S44-S52.
38. Dearden C, Matutes E, Cazin B, et al. High remis-
sion rate in T-cell prolymphocytic leukemia with
CAMPATH-1H. Blood. 2001;98:1721-1726.
39. Lundin J, Hagberg H, Repp L, et al. Phase 2
study of alemtuzumab (anti-CD52 monoclonal
antibody) in patients with advanced mycosis fun-
goides/Sezary syndrome. Blood. 2003;101:4267-
4272.
40. Osuji N, Del Giudice I, Matutes E, et al. CD52 ex-
pression in T-cell large granular lymphocytic leu-
kemia: implications for treatment with alemtu-
zumab. Leuk Lymphoma. 2005;46:723-727.
41. Emblad G, Hagberg H, Ertanson M, et al. A pilot
study of alemtuzumab (anti-CD52 monoclonal
antibody) therapy for patients with relapsed or
chemotherapy-refractory peripheral T-cell lym-
phoma. Blood. 2004;103:2920-2924.
42. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab
plus CHOP as front-line chemotherapy for pa-
tients with peripheral T-cell lymphomas: a phase
II study. Cancer Chemother Pharmacol. 2007;1:
129-134.
43. Piccaluga PP, Agostinelli C, Righi S, et al. Ex-
pression of CD52 in peripheral T-cell lymphoma.
Haematologica. 2007;92:566-567.
44. Golay J, Manganini M, Rambaldi A, et al. Effect of
alemtuzumab on neoplastic B cells. Haemato-
logica. 2004;89:1476-1483.
45. Maertens J, Verhaegen L, Lagrou K, et al.
Screening for galactomannan as a noninvasive
diagnostic tool for invasive aspergillosis in pro-
longed neutropenic patients and stem cell trans-
plantation recipients: a prospective validation.
Blood. 2001;97:1604-1610.
46. Ramadan G, Davies B, Kurup VP, et al. Genera-
tion of Th1 T cell responses directed to a HLA
class II restricted epitope from the aspergillus f16
allergen. Clin Exp Immunol. 2005;139:257-267.
47. Sallah S, Wan JY, Nguyen NP. Treatment of re-
fractory T-cell malignancies using gemcitabine.
Br J Haematol. 2001;113:185-187.
48. Arkenau HT, Chong G, Cunningham D, et al.
Gemcitabine, cisplatin and methylprednisolone
for the treatment f patients with peripheral T-cell
lymphoma: the Royal Marsden Hospital experi-
ence. Haematologica. 2007;92:271-272.
49. Piekarz RL, Frye R, Turner M, et al. Responses
and molecular markers in patients with peripheral
T-cell lymphoma treated on a phase II trial of dep-
sipeptide, FK228. Proc Annu Meet Am Assoc
Cancer Res. 2005;24:3061.
50. O’Connor OA, Heaney M, Schwartz L, et al. Clini-
cal experience with intravenous and oral formula-
tions of the novel histone deacetylase inhibitor
suberoylanilide hydroxamic acid in patients with
advanced hematologic malignancies. J Clin On-
col. 2006;24:166-173.
51. Czuczman MS, Porcu PL, Johnson J, et al. Re-
sults of a phase II study of 506U78 in cutaneous
T-cell lymphoma and peripheral T-cell lymphoma:
CAGB 59901. Leuk Lymphoma. 2007;48:97-103.
52. O’Connor OA: Pralatrexate: an emerging new
agent with activity in T-cell lymphomas Corr Opin
Oncol. 2006;18:591-597.
53. Corradini P, Dodero A, Zallio F, et al. Graft-ver-
sus-lymphoma effect in relapsed peripheral T-cell
non-Hodgkin’s lymphomas after reduced-intensity
conditioning followed by allogeneic transplanta-
tion. J Clin Oncol. 2004;22:2172-2176.
CHOP, Campath-1H, PTCL 2323BLOOD, 1 OCTOBER 2007  VOLUME 110, NUMBER 7  personal use only.
For at Biblioteche biomediche Università di Torino on May 18, 2012. bloodjournal.hematologylibrary.orgFrom 
